XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
  Diabetes
   Insulin Resistance
   NIDDM
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate
Search

Last Updated: Nov 18, 2006 - 1:55:25 PM
Research Article

Insulin Resistance Channel
subscribe to Insulin Resistance newsletter

Latest Research : Endocrinology : Diabetes : Insulin Resistance

   DISCUSS   |   EMAIL   |   PRINT
Elevation of fat-derived molecule RBP4 foretells early insulin resistance
Jun 15, 2006 - 4:39:00 PM, Reviewed by: Dr. Sanjukta Acharya

The new findings offer a potential new target for the development of anti-diabetic therapies to lower serum RBP4 levels as well as an early means of identifying individuals who are at risk of developing diabetes � before the onset of overt disease.

 
A study in the June 15 issue of The New England Journal of Medicine (NEJM) reveals that elevated levels of a molecule called RBP4 (retinol binding protein 4) can foretell early stages in the development of insulin resistance, a major cause of type 2 diabetes as well as cardiovascular disease.

The new findings, led by researchers at Beth Israel Deaconess Medical Center (BIDMC), offer a potential new target for the development of anti-diabetic therapies to lower serum RBP4 levels as well as an early means of identifying individuals who are at risk of developing diabetes � before the onset of overt disease.

"Type 2 diabetes is a rapidly increasing epidemic in the Western world," explains senior author Barbara Kahn, MD, Chief of the Division of Diabetes, Endocrinology and Metabolism at BIDMC and Professor of Medicine at Harvard Medical School. "Since it is now occurring even in childhood, predictions indicate that it could shorten lifespan in the U.S. for the first time in more than a century."

Insulin resistance develops when the body's muscles, fat and liver cells lose the ability to respond to the hormone insulin. Because insulin is necessary to enable the body to take up sugar from blood and convert it into energy, this impairment results in a buildup of glucose in the bloodstream.

"Insulin resistance not only predisposes individuals to type 2 diabetes, it is also a major risk factor for cardiovascular disease," adds co-lead author Timothy Graham, MD, an investigator in the Kahn laboratory. "Unfortunately, in the clinical setting, it is often difficult to distinguish individuals with and without insulin resistance."

Last year, in a study conducted in animals, Kahn's laboratory made the discovery that RBP4, a protein secreted from fat, can cause insulin resistance. Prior to this, the molecule was recognized only for its role in the transport of vitamin A.

In this new research, Graham, together with co-lead author Qin Yang, MD, PhD, set out to determine whether levels of RBP4, as measured in blood, correlate with the presence or absence of insulin resistance. (Study subjects represented three separate cohorts from San Diego, California; Goteberg, Sweden; and Leipzig, Germany.)

They first studied individuals with either obesity, impaired glucose tolerance (a "pre-diabetic" state), or with type 2 diabetes, comparing the blood levels of RBP4 in these insulin-resistant subjects with levels found in non-obese healthy subjects. Their results showed that not only were RBP4 levels higher in all cases in which insulin resistance was high, but that elevated serum RBP4 was also closely associated with components of the metabolic syndrome, including increased body mass index, waist-to-hip ratio, serum triglyceride levels, and systolic blood pressure, as well as decreased levels of high-density lipoprotein (HDL), or good, cholesterol.

The study was then extended to subjects with normal body weight and normal blood glucose, but with a strong family history of type 2 diabetes. "These are people who appear healthy, but have a high risk of developing diabetes due to their genetic background," explains Ulf Smith, MD, PhD, of Sahlgrenska Hospital, Goteberg, Sweden, where this group of subjects was based. As predicted, the investigators found elevated RBP4 levels among this group as well.

Finally, the authors tested whether a therapeutic intervention � in this case, exercise � could lower RBP4 levels and increase insulin sensitivity. They found that all of the people who improved their insulin sensitivity with exercise also lowered their serum RBP4 levels. Among the one-third of the subjects who did not improve their insulin sensitivity, neither did RBP4 levels go down.

"Collectively, these findings tell us that RBP4 is a useful marker for therapeutic improvement and that this protein could play a causal role in insulin resistance in humans, just as our lab previously showed in mice," says Kahn. Furthermore, she adds, because RBP4 levels consistently corresponded with insulin resistance -- even among lean subjects whose genetic risk for the development of diabetes might otherwise be overlooked -- this protein could be an important marker for type 2 diabetes among the general population.

"Being able to determine diabetes risk well before the onset of symptoms could provide an important opportunity for patients to take preventive measures," she adds. "For those who are overweight or sedentary, this could mean making changes to their diet and fitness routines. For those who are lean and fit, but have a family history of type 2 diabetes, this could mean taking antidiabetic medication. Either way, these findings could help clinicians to better manage this growing epidemic."
 

- June 15 issue of The New England Journal of Medicine (NEJM)
 

www.bidmc.harvard.edu

 
Subscribe to Insulin Resistance Newsletter
E-mail Address:

 

In addition to Kahn, Graham and Yang, study coauthors include Christopher Watson of BIDMC; Matthias Bluher, MD and Andreas Oberbach, MD, of the University of Leipzig Medical Center, Germany; Ann Hammarstedt, PhD, Per-Anders Jansson, MD, PhD, and Ulf Smith, MD, PhD, of Sahlgrenska University Hospital, Goteborg, Sweden; and Theodore Ciaraldi, PhD and Robert Henry, MD, of the Veterans Affairs San Diego Healthcare System.

This study was funded, in part, by grants from the National Institutes of Health, the American Diabetes Association, the Swedish Diabetes Association, and the Takeda Pharmaceutical Company, LTD.

Beth Israel Deaconess Medical Center is a patient care, research and teaching affiliate of Harvard Medical School and ranks fourth in National Institutes of Health funding among independent hospitals nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and is a research partner of the Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.harvard.edu.


Related Insulin Resistance News
PAI-1 is the link between diabetes and cardiovascular disease
Insulin inhibits resistin expression and secretion
Insulin resistance in early teens may predict diabetes
Race may be risk factor for insulin resistance
Elevation of fat-derived molecule RBP4 foretells early insulin resistance
Insulin Resistance Linked to Pancreatic Cancer
Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of langerhans
Insulin Resistance May Be the Result of Mitochondrial Dysfunction


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us